PT - JOURNAL ARTICLE AU - Thomas Wiedl AU - Stéphane Collaud AU - Sven Hillinger AU - Stephan Arni AU - Chris Burgess AU - Werner Kroll AU - Peter Schraml AU - Alex Soltermann AU - Holger Moch AU - Walter Weder TI - <em>KRAS</em> Mutation Is Associated with Elevated Myeloblastin Activity in Human Lung Adenocarcinoma DP - 2012 Jan 01 TA - Cancer Genomics - Proteomics PG - 51--54 VI - 9 IP - 1 4099 - http://cgp.iiarjournals.org/content/9/1/51.short 4100 - http://cgp.iiarjournals.org/content/9/1/51.full SO - Cancer Genomics Proteomics2012 Jan 01; 9 AB - Lung cancer is the leading cause of all cancer deaths worldwide with suboptimal prognosis and treatment options. Therefore this study aimed to identify molecular characteristics with a predictive clinical utility which at the same time might represent novel therapeutic targets for human lung adenocarcinoma. Within this study mutations of v-Ki-RAS2 Kirsten rat sarcoma viral oncogene homolog (KRAS), a gene frequently mutated in lung adenocarcinoma, and their association with enzymatic activities, as assessed by activity-based proteomics, of members of the serine hydrolase (SH) superfamily, a large class of enzymes that have previously been linked to cancer was investigated. The results revealed that the activity of myeloblastin was significantly altered in the lung adenocarcinoma biopsies harboring a KRAS gene mutation. In conclusion myeloblastin is a potential therapeutic target for human lung adenocarcinoma, indicating that the combination of activity-based proteomics with mutational analysis is a valid approach for the discovery of novel biomarkers.